Teva Pharmaceutical Industries Ltd. has agreed to settle accusations that its marketing of opioid medications increased the operational costs of U.S. hospitals by up to $126 million over 18 years. The Israeli pharmaceutical company Teva also promised to provide $49 million worth of the overdose-reversing medicine naloxone as part of the proposed settlement, which was announced in Teva’s quarterly earnings report on Wednesday.
